Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06RYY
|
||||
| Former ID |
DIB008803
|
||||
| Drug Name |
ZD-9379
|
||||
| Indication | Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] | Phase 1 | [1], [2] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c12c([n-]c3c(c2=O)ccc(c3)Cl)c(=O)[nH]n(c1=O)c1c(cc(cc1)<br />OC)C.[Na+]
|
||||
| CAS Number |
CAS 170142-20-8
|
||||
| Target and Pathway | |||||
| Target(s) | Glycine receptor | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Ligand-gated ion channel transport | ||||
| WikiPathways | Iron uptake and transport | ||||
| References | |||||
| REF 1 | Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26. | ||||
| REF 2 | A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke. 1998 Jan;29(1):190-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.